Group items tagged

The future outlook for organic surface-active agents to 2017 looks promising. Key insights into the organic surface-active agent market in Americas help gain a complete picture of the historic development, current market situation and trends. Anionic surface-active agents, cationic surface-active agents, non-ionic surface active agents and other organic surface-active agents together constitute the major share of organic surface-active agent markets in America.

Analysis of the organic surface-active agent markets in Eastern Europe by product types unfolds emerging opportunities and attracts investments. Key product segments include anionic surface-active agents, cationic surface-active agents and non-ionic surface active agents.

Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012, comprising Aventis Taxotere (docetaxel), Bristol-Myers Squibbs Paraplatin (carboplatin) and Eli Lillys Gemzar (gemcitabine). The third-generation chemotherapeutic agents have expanded the therapeutic options in the treatment of advanced lung cancer. However, despite their contributions, science has reached a therapeutic plateau.

Diabetic foot ulcers (DFUs) are a common complication of diabetes. With the increasing prevalence of diabetes across all markets the number of patients suffering from DFUs is also expected to rise. The global DFU therapeutics market is set to enter an exciting phase with the potential launch of three wound-healing agents in the next five years. The first two topical antibacterial are also expected to be launched in the US and the five major EU markets. With the advent of these new product launches, the size of the DFU market is expected to grow substantially by 2017.